Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

pemlimogene merolisbac (JNJ-64041757)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

EGFR inhibitor, Mesothelin inhibitor

Related drugs:

‹

anti-Mesothelin CAR NK Cells (0)

autologous redirected RNA meso-CIR T cells (0)

BAY 2287411 (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

furmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

FH-TCR-Tᴍsʟɴ (0)

anti-Mesothelin CAR NK Cells (0)

autologous redirected RNA meso-CIR T cells (0)

BAY 2287411 (0)

›